Please assess the completion status of the following clinical trial:

Trial Title: Protective Effects of Sitagliptin on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes (LADA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diabetes diagnosed according to the report of WHO in 1999.~2. Age at onset between 25\~70 years.~3. Disease duration of less than 3 year.~4. No ketoacidosis within the first 6 months after diagnosis of diabetes.~5. GADA positive twice within one month.~6. Fasting C-peptide (FCP) level of 0.2 nmol/L or more.~Exclusion Criteria:~1. Insulin requirements more than 0.8 units/kg/day.~2. Evidence of chronic infection or acute infection affected blood glucose control within 4 weeks prior to visit 1.~3. History of any malignancy.~4. Pregnancy, breastfeeding or planned pregnancy within two years.~5. Secondary diabetes.~6. Congestive heart failure requiring pharmacologic treatment.~7. Renal disease or renal dysfunction or diabetic nephropathy suggested by serum creatinine levels≥1.5 mg/dL (132μmol/L) for males and ≥1.4mg/dL (123μmol/L) for females or abnormal creatinine clearance at Visit 1.~8. Concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Patients will receive insulin therapy with sitagliptin.
- Insulin (Type: ACTIVE_COMPARATOR): Patients will receive insulin therapy without sitagliptin.

Based on this trial design, predict the completion outcome and termination type (if applicable).